DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28858479
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28858479
Streptovaricins (or streptovarycins) are a group of structurally related macrolide antibiotics, which are active against gram-positive and gram-negative bacteria and especially against Mycobacterium tuberculosis. It was shown, that streptovaricin probably blocked transcription of adenovirus 2 (AD2) by inhibiting early transcription complex assembly events.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: early transcription complex assembly Sources: https://www.ncbi.nlm.nih.gov/pubmed/2905235 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Functional Analysis of Cytochrome P450s Involved in Streptovaricin Biosynthesis and Generation of Anti-MRSA Analogues. | 2017-10-20 |
|
| Involvement of the beta subunit of RNA polymerase in resistance to streptolydigin and streptovaricin in the producer organisms Streptomyces lydicus and Streptomyces spectabilis. | 2010-05 |
|
| [Effect of streptovaricin on the multiplication of L line cells]. | 1978 |
|
| Streptovaricins inhibit focus formation by MSV (MLV) complex. | 1971-08 |
|
| Inhibition of nucleoside incorporation into HeLa cells by streptovaricin. | 1971-01-22 |
|
| [Streptovaricin, a new antibiotic; effects on Mycobacterium tuberculosis in vitro]. | 1958-05-01 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/81565
Streptovaricin inhibited the L cell multiplication, rendering no significant effect on that of normal fibroblasts of C3H mice culture. In a dose of 4 mkg/ml streptovaricin would induce an increase of the DNA amount in L cell nuclei, while its dosage of 8 mkg/ml decrease the amount of DNA, resulting in the differentiation of some population cells.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 21:02:24 GMT 2025
by
admin
on
Mon Mar 31 21:02:24 GMT 2025
|
| Record UNII |
FN6FE63EQE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C261
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m10230
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
C152439
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
19989
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
100000085047
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
684
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
FN6FE63EQE
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
SUB04594MIG
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108868
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
1404-74-6
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
DTXSID501023446
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |